An Evolution in Name, Structure, and Strategy Reflecting the Company’s AI-Driven Platform and Bio-Native Discovery Vision ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), ImmunoPrecise Antibodies Ltd. and its subsidiaries (BioStrand and Talem) at this time introduced a unification below a single company model, MindWalk, and a change of its Nasdaq ticker image to HYFT. The…
Manufacturing of validated dengue epitope underway; proprietary immunization research in rabbit mannequin to evaluate monoclonal antibody (mAb) responses. ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Firm”), a biotherapeutics firm delivering superior options in biologics and drug discovery in the present day introduced the following milestone in its common dengue vaccine program. Constructing on its…
Firm broadcasts acquisition of Aster Insights, a transfer that creates a first-of-its-kind enterprise aimed toward accelerating the event of most cancers therapies Zephyr AI, Inc. (“Zephyr AI”), a pacesetter in precision drugs harnessing synthetic intelligence to speed up drug improvement, in the present day introduced that it has appointed Allen Chao, PhD, as its Chief…
Allow approval allows expanded analysis capabilities and underscores dedication to accuracy, reliability, and scientific excellence Quanterix Company (NASDAQ: QTRX), an organization fueling scientific discovery via ultrasensitive biomarker detection, right this moment introduced the New York State Division of Well being (NYSDOH) has granted the Quanterix Accelerator Laboratory a scientific laboratory allow within the Medical Chemistry class. The allow…
At-home participation in a study by Scripps Research and Schmidt Initiative for Long Covid powered by CareEvolution’s MyDataHelps® platform Long Covid patients around the U.S. looking to participate in a clinical trial from home can sign up to be notified when an upcoming study conducted by scientists at Scripps Research and supported by the Schmidt…
Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting Alamar Biosciences, a company pioneering precision proteomics to drive the earliest detection of disease, today announced the presentation of NULISA data in over 30 scientific sessions and poster presentations at the AAIC conference held July 27-31 in Toronto, Canada. The NULISA platform…
Company highlights expanded capabilities following Akoya Biosciences Acquisition and Simoa® technology included in more than 55 posters and oral presentations at the annual conference demonstrating its impact on neurodegenerative disease research Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the first to market, commercial launch of two novel phospho-tau…
The EU patent allowance strengthens the prior patent allowance for LP-284 in the US, Japan India and Mexico. LP-284 has the potential to address B-cell lymphomas and other B-cell driven malignancies addressing a $4+ billion annual market need LP-284 is in an active Phase 1 trial in the US focused on lymphomas and other B-cell…
OpenFold Consortium’s new members will bring privacy-preserving, AI infrastructure and collaboration on proprietary data to the Consortium OpenFold Consortium, an open science initiative advancing foundational AI tools for biological applications, announced today that Apheris and Johnson & Johnson have joined the consortium as new members. This collaboration marks a significant step forward in the effort…
Pharma teams can now assess biomarker coverage across datma’s federated network with no cost, contracts, or IT support required. datma, a leader in federated real-world data access, today announced the launch of the Federated Biomarker Explorer, a new application that allows pharmaceutical teams to evaluate real-world biomarker coverage across datma’s federated network of participating data contributors…